References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2019-3-127-140

vtio-1072

Research Article

Обзор литературы

Literature Reviews

Неалкогольная жировая болезнь печени – быстро растущее показание к трансплантации печени в современном мире

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world

Ильинский

И. М.

Iljinsky

I. M.

Ильинский Игорь Михайлович. Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (999) 877-60-95.

Iljinsky Igor Mihajlovich. Address: 1, Shchukinskaya str., Moscow, 123182. Тел. (999) 877-60-95.

iiljinsky@mail.ru

Цирульникова

О. М.

Tsirulnikova

O. M.

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian Federation

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)Russian Federation

2019

01102019

213127140

2019

Ильинский И.М., Цирульникова О.М.

Iljinsky I.M., Tsirulnikova O.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/1072

Неалкогольная жировая болезнь печени (НАЖБП) является наиболее частой причиной хронических заболеваний печени во многих странах, с вовлечением около 25% населения во всем мире. Это заболевание включает множество генетических, метаболических и экологических факторов. Оно тесно связано с инсулинорезистентностью, метаболическим синдромом, ожирением, сахарным диабетом и многими другими заболеваниями. Неалкогольная жировая болезнь печени характеризуется макровезикулярным стеатозом печени. При естественном течении НАЖБП простой стеатоз прогрессирует до неалкогольного стеатогепатита (НАСГ), фиброза и в конечном счете до цирроза и гепатоцеллюлярной карциномы. Цирроз при НАСГ и гепатоцеллюлярная карцинома являются показанием для трансплантации печени. Ожирение является растущей проблемой у кандидатов на трансплантацию печени. Сердечно-сосудистые осложнения, связанные с метаболическим синдромом, и рецидив НАСГ в трансплантированной печени могут повлиять на исход операции у этих пациентов. Результаты после трансплантации схожи с результатами трансплантации печени по другим показаниям, но сердечно-сосудистые осложнения являются основной причиной смерти больных с НАСГ после операции.

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in many countries, involving about 25% of the population worldwide. This disease includes many genetic, metabolic, and environmental factors. It is closely associated with insulin resistance, metabolic syndrome, obesity, diabetes, and many other diseases. NAFLD is characterized by macrovesicular steatosis of the liver. In the natural course of NAFLD simple steatosis progresses to nonalcoholic steatohepatitis (NASH), fibrosis and ultimately, cirrhosis and hepatocellular carcinoma. Cirrhosis with Nash and hepatocellular carcinoma is an indication for liver transplantation. Obesity is a growing problem in liver transplant candidates. Cardiovascular complications related to metabolic syndrome and NASH recurrence in the transplanted liver may affect the outcome of surgery in these patients. The results after transplantation are similar to the results of liver transplantation for other indications, but cardiovascular complications are the main cause of death in patients with NASH after surgery.

неалкогольная жировая болезнь печенинеалкогольный стеатогепатиттрансплантация печени

nonalcoholic fatty liver diseasenonalcoholic steatohepatitisliver transplantation

References1

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980 Jul; 55 (7): 434–438.

Patel YA, Berg CL, Moylan CA. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci. 2016 May; 61 (5): 1406–1416. doi: 10.1007/s10620-016-4035-3.

Kappus M, Abdelmalek M. De novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clin Liver Dis. 2017 May; 21 (2): 321–335. doi: 10.1016/j.cld.2016.12.006.

Calzadilla-Bertot L, Jeffrey GP, Jacques B, McCaughan G, Crawford M, Angus P et al. Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. Liver Transpl. 2019 Jan; 25 (1): 25–34. doi: 10.1002/ lt.25361.

Волкова НИ, Поршеян МИ. Неалкогольная жировая болезнь печени: что мы знаем и что предстоит узнать. Тер. архив. 2017; 2: 91–98. Volkova NI, Porsheyan MI. Nonalcoholic fatty liver disease: what we know and what remains to be known. Ter. archive (Russian). 2017; 2: 91–98. [In Russ, English abstract] doi: 10.17116/ terarkh201789291-98.

Мишина ЕЕ, Майоров АЮ, Богомолов ПО, Мациевич МВ, Кокина КЮ, Боголюбова АВ. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017; 20 (5): 335–342. Mishina EE, Mayorov AYu, Bogomo lov PO, Matsievich MV, Kokina KYu, Bogolyubova AV. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes. 2017; 20 (5): 335–342. [In Russ, English abstract] doi: 10.14341/DM9372.

Никонов ЕЛ, Аксенов ВА. Современные подходы к диагностике и лечению неалкогольной жировой болезни печени. Профилактическая медицина. 2018; 21 (3): 62–69. Nikonov EL, Aksenov VA. Modern approaches to the diagnosis and treatment of nonalcoholic fatty liver disease. Preventive medicine. 2018; 21 (3): 62–69. [In Russ, English abstract] doi: 10.17116/profmed201831262.

Полухина АВ, Винницкая ЕВ, Хайменова ТЮ, Сандлер ЮГ. Неалкогольный стеатогепатит: проблема современной диагностики. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2018; 1: 23–29. Polukhina AV, Vinnitskaya EV, Khaymenova TYu, Sandler YuG. Non-alcoholic steatohepatitis: a problem of modern diagnostics. Gastroenterology. The Supplement to the journal Consilium Medicum. 2018; 1: 23–29. [In Russ, English abstract] doi: 10.26442/24143529_2018.1.23-29.

Степанов ЮМ, Недзвецкая НВ, Ягмур ВБ, Кленина ИА. Неалкогольная жировая болезнь печени: особенности метаболических изменений на разных этапах развития болезни. Гастроэнтерология. 2018; 52 (1): 13–18. Stepanov YuM, Nedzvetskaya NV, Yagmur VB, Klenina IA. Non-alcoholic fatty liver disease: features of metabolic changes at different stages of the disease. Gastroenterology. 2018; 52 (1): 13–18. [In Russ, English abstract] doi: 10.22141/2308-2097.52.1.2018.130772.

Сучкова ЕВ. Неалкогольная жировая болезнь печени: клинические и лабораторно-инструментальные особенности функции печени и желчевыводящих путей, эффективность комбинированной терапии: Дис. … д-ра мед. наук. Ижевск, 2017. 200 с. Suchkova EV. Nonalcoholic fatty liver disease: clinical and laboratoryinstrumental features of liver function and biliary tract, the effectiveness of combination therapy. [Dissertation]. Izhevsk, 2017. 200 p.

Кутырева ЕН, Павловская ЕВ, Сурков АГ, Строкова ТВ, Каганов БС, Павлючкова МС, Сенцова ТБ. Клинико-метаболические особенности неалкогольной жировой болезни печени у детей. Вопросы детской диетологии. 2014; 12 (6): 5–13. Kutyreva EN, Pavlovskaya EV, Surkov AG, Strokova TV, Kaganov BS, Pavlyuchkova MS, Sentsova TB. Clinical and metabolic characteristics of non-alcoholic fatty bolez-or of the liver in children. Questions of children’s dietetics. 2014; 12 (6): 5–13. [In Russ, English abstract].

Российское общество по изучению печени. Методические рекомендации для врачей. Диагностика и лечение неалкогольной жировой болезни печени / Под ред. акад. РАН, проф. В.Т. Ивашкина. М., 2015. 38 с. Russian society for the study of the liver. Guidelines for doctors. Diagnosis and treatment of nonalcoholic fatty liver disease / Edited by academician of RAS, Professor V.T. Ivashkin. M., 2015. 38 p. [In Russ].

Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018 Feb; 22 (1): 11–21. doi: 10.1016/j. cld.2017.08.003.

Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol. 2017 Dec 28; 5 (4): 384–393. doi: 10.14218/JCTH.2017.00013.

Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018 Feb; 68 (2): 326–334. doi: 10.1016/j.jhep.2017.10.006.

Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014 May 14; 20 (18): 5320–5330. doi: 10.3748/ wjg.v20.i18.5320.

Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 Apr; 152 (5): 1090–1099.e1. doi: 10.1053/j.gastro.2017.01.003.

Holmer M, Melum E, Isoniemi H, Ericzon BG, Castedal M, Nordin A et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int. 2018 Nov; 38 (11): 2082– 2090. doi: 10.1111/liv.13751.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul; 64 (1): 73–84. doi: 10.1002/hep.28431.

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug; 34 (3): 274–285. doi: 10.1111/j.1365-2036.2011.04724.x.

Sayiner M, Younossi ZM. Nonalcoholic Steatohepatitis Is Becoming a Top Indication for Liver Transplantation Worldwide. Liver Transpl. 2019 Jan; 25 (1): 10–11. doi: 10.1002/lt.25387.

Цуканов ВВ, Тонких ЮЛ, Каспаров ЭВ, Куперштейн ЕЮ, Амельчугова ОС, Лукичева ЭВ, Васютин АВ. Hеалкогольная жировая болезнь печени у взрослого городского населения России (Распространенность и факторы риска). Врач. 2010; 9: 1–4. Tsukanov VV, Tonkikh YuL, Kasparov EV, Kuperstein EYu, Amelchugova OS, Lukicheva EV, Vasyutin AV. Nonalcoholic fatty liver disease in adult urban population of Russia (Prevalence and risk factors). Vrach. 2010; 9: 1–4. [In Russ, English abstract].

Драпкина ОМ, Ивашкин ВТ. Эпидемиологические особенности неалкогольной жировой болезни печени в России. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014; 4: 32–38. Drapkina OM, Ivashkin VT. Epidemiological features of nonalcoholic fatty liver disease in Russia. Russian journal of gastroenterology, hepatology, coloproctology. 2014; 4: 32–38. [In Russ, English abstract].

Пальгова ЛК, Барановский АЮ, Ушакова ТИ, Юркина АС, Блинов ДВ. Эпидемиологические особен ности неалкогольной жировой болезни печени в Cеверо-Западном регионе России (результаты открытого многоцентрового проспективного исследования DIREG 2). Вестник СПбГУ. Медицина. 2017; 12 (2): 118–135. Palgova LK, Baranovsky AYu, Ushakova TI, Yurkina AS, Blinov DV. Epidemiological features of nonalcoholic fatty liver disease in the North-Western region of Russia (Results of a open multicenter prospective study DIREG 2). Bulletin of St. Petersburg state University. Medicine. 2017; 12 (2): 118–135. [In Russ, English abstract]. doi: 10.21638/11701/spbu11.2017.201.

Ивашкин ВТ, Драпкина ОМ, Маев ИВ, Трухманов АС, Блинов ДВ, Пальгова ЛК и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31–41. Ivashkin VT, Drapkina OM, Mayev IV, Trukhmanov AS, Blinov DV, Palgova LK et al. Prevalence of non-alcoholic fatty liver disease patients to polyclinic practices in the Russian Federation: the results of the study DIREG 2. Russian journal of gastroenterology, hepatology, coloproctology. 2015; 6: 31–41. [In Russ, English abstract].

Mendez-Sanchez N, Zamarripa-Dorsey F, Panduro A, Purón-González E, Coronado-Alejandro EU, CortezHernández CA et al. Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions. World J Clin Cases. 2018 Dec 6; 6 (15): 922–930. doi: 10.12998/wjcc.v6.i15.922.

Farrell GC, Wong VW, Chitturi S. NAFLD in Asia – as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013 May; 10 (5): 307–318. doi: 10.1038/nrgastro.2013.34.

Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan; 67 (1): 123–133. doi: 10.1002/hep.29466.

Богомолов ПО, Кокина КЮ, Майоров АЮ, Мишина ЕЕ. Генетические аспекты неалкогольной жировой болезни печени. Вопросы современной педиатрии. 2018; 17 (6): 442–448. Bogomolov PO, Kokina KYu, Mayorov AYu, Mishina EE. Genetic aspects of non-alcoholic fatty liver disease. Questions of modern Pediatrics. 2018; 17 (6): 442–448. [In Russ, English abstract] doi: 10.15690/vsp.v17i6.1974.

Golabi P, Paik J, Reddy R, Bugianesi E, Trimble G, Younossi ZM. Prevalence and long-term outcomes of nonalcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol. 2019 Apr 16; 19 (1): 56. doi: 10.1186/s12876-019-0972-6.

Liu A, Galoosian A, Kaswala D, Li AA, Gadiparthi C, Cholankeril G et al. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. J Clin Transl Hepatol. 2018 Dec 28; 6 (4): 420–424. doi: 10.14218/JCTH.2018.00010.

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov; 10 (11): 686–690. doi: 10.1038/nrgastro.2013.171.

Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I et al. Nonalcoholic fatty liver disease and liver transplantation – Where do we stand? World J Gastroenterol. 2018 Apr 14; 24 (14): 1491–1506. doi: 10.3748/wjg.v24.i14.1491.

Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P et al. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016 Dec; 65 (6): 1245–1257. doi: 10.1016/j.jhep.2016.07.033.

Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci. 2019 Jan 1; 16 (2): 285–291. doi: 10.7150/ijms.28264.

Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D et al. Predictors of de novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019 Jan; 25 (1): 56–67. doi: 10.1002/lt.25338.

Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017 Jan; 14 (1): 32–42. doi: 10.1038/nrgastro.2016.147.

Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol. 2015 Dec 15; 418 Pt 1: 55–65. doi: 10.1016/j.mce.2015.02.018.

Ren XY, Shi D, Ding J, Cheng ZY, Li HY, Li JS et al. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis. 2019 Feb 11; 18 (1): 47. doi: 10.1186/s12944-019-0984-9.

Борсуков АВ, Венидиктова ДЮ. Оценка сравнительной эффективности методов инструментальной диагностики стеатоза печени у пациентов с метаболическим синдромом. Практическая медицина. 2018; 2: 16–21. Borsukov AV, Venidiktova DYu. Evaluation of the comparative effectiveness of methods of instrumental diagnosis of liver steatosis in patients with metabolic syndrome. Practical medicine. 2018; 2: 16–21. [In Russ, English abstract].

Бакулин ИГ, Сандлер ЮГ, Винницкая ЕВ, Кейян ВА и др. Сахарный диабет и неалкогольная жировая болезнь печени: грани сопряженности. Терапевтический архив. 2017; 2: 59–65. Bakulin IG, Sandler YuG, Vinnitskaya EV, Keyan VA et al. Diabetes and nonalcoholic fatty liver disease: the edge of contingency. Therapeutic archive. 2017; 2: 59–65. [In Russ, English abstract].

Шаронова ЛА. Взаимосвязь неалкогольной жировой болезни печени и сахарного диабета 2-го типа. РМЖ. 2017; 22: 1635–1640. Sharonova LA. The Relationship of nonalcoholic fatty liver disease and type 2 diabetes. BC. 2017; 22: 1635–1640. [In Russ, English abstract].

Pelaez-Jaramillo MJ, Cárdenas-Mojica AA, Gaete PV, Mendivil CO. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Ther. 2018 Apr; 9 (2): 521–543. doi: 10.1007/s13300-018-0374-8.

Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016. September; 65 (3): 589–600.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018 Feb; 68 (2): 335–352. doi: 10.1016/j.jhep.2017.09.021.

Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol. 2018 Mar; 68 (3): 519–525. doi: 10.1016/j. jhep.2017.11.018.

Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int. 2015; 2015: 460190. doi: 10.1155/2015/460190.

Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016 Jun; 150 (8): 1728–1744.e7. doi: 10.1053/j.gastro.2016.01.037.

Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017 Jun; 49 (6): 842–847. doi: 10.1038/ ng.3855.

Тихомирова АС, Кисляков ВА, Байкова ИЕ, Никитин ИГ. Клинико-морфологические параллели полиморфизма гена PNPLA3 у пациентов с неалкогольной жировой болезнью печени. Терапевтический архив. 2018; 90 (02): 85–88. Tikhomirova AS, Kislyakov VA, Baykova IE, Nikitin IG. Clinical-morphological parallels of the PNPLA3 gene polymorphism in patients with nonalcoholic fatty liver disease. Terapevticheskij archiv. 2018; 90 (02): 85–88. [In Russ, English abstract]. doi: 10.26442/terarkh201890285-88.

Kupcinskas J, Valantiene I, Varkalaitė G, Steponaitiene R, Skieceviciene J, Sumskiene J et al. PNPLA3 and RNF7 Gene Variants are Associated with the Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population. J Gastrointestin Liver Dis. 2017 Mar; 26 (1): 37–43. doi: 10.15403/jgld.2014.1121.261. pnp.

Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, Ness T et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015 Mar 14; 7: 25. doi: 10.1186/s13148-015-0056-6.

Топчиева ЛВ, Курбатова ИВ, Дуданова ОП, Соколовская АА, Шиповская АА. Полиморфный вариант RS2228145 (С>A) гена IL6R как маркер генетической предрасположенности у русского населения Карелии к развитию неалкогольного стеатогепатита. Бюллетень экспериментальной биологии и медицины. 2018; 165 (1): 75–79. Topchieva LV, Kurbatova IV, Dudanova OP, Sokolovskaya AA, Shipovskaya AA. IL6R Gene Polymorphic Variant rs2228145 (C>A) as a Marker of Genetic Liability to Nonalcoholic Steatohepatitis in the Russian Population of Karelia. Bulletin of Experimental Biology and Medicine. 2018; 165 (1): 75–79. [In Russ, English abstract].

Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res Off J Jpn Soc Hepatol. 2016. October; 46 (11): 1074–87. doi: 10.1111/hepr.12656.

Шевченко ОП, Цирульникова ОМ, Курабекова РМ, Цирульникова ИЕ, Олефиренко ГА, Готье СВ. Уровень трансформирующего фактора роста β1 в плазме крови детей – реципиентов печени и его связь с функцией трансплантата. Иммунология. 2015; 36 (6): 343–347. Shevchenko OP, Tsirulnikova OM, Kurabekova RM, Tsirulnikova IE, Olefirenko GA, Gautier SV. Level of transforming growth factor β1 in the blood plasma of child recipients of liver and its relation with the function of the transplant. Immunology. 2015; 36 (6): 343–347. [In Russ, English abstract].

Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010 Nov 14; 16 (42): 5286–5296. doi: 10.3748/wjg.v16.i42.5286.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan; 67 (1): 328–357. doi: 10.1002/ hep.29367.

Day CP. From fat to inflammation. Gastroenterology. 2006; 130: 207–210. doi: 10.1053/j.gastro.2005.11.017.

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015 Apr; 13 (4): 643–654. e1–9; quiz e39–40. doi: 10.1016/j.cgh.2014.04.014.

Bertot LC, Jeffrey GP, Wallace M, MacQuillan G, Garas G, Ching HL, Adams LA. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun. 2017 Feb 27; 1 (1): 53–60. doi: 10.1002/hep4.1018.

Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2018 Dec 12; 6 (4): 1801585. doi: 10.1002/advs.201801585.

Шиповская АА, Дуданова ОП, Курбатова ИВ. Клиническое значение инсулинорезистентности у недиабетических пациентов с ранними формами неалкогольной жировой болезни печени. Терапевтический архив. 2018; 90 (8): 63–68. Shipovskaya AA, Dudanova OP, Kurbatova IV. Clinical significance on insulin resistance in non-diabetic patients with early forms on nonalcoholic fatty liver disease. Therapeutic archive. 2018; 90 (8): 63–68. [In Russ, English abstract]. doi: 10.26442/terarkh201890863-68.

Tsochatzis E, Coilly A, Nadalin S, Levistky J, Tokat Y, Ghobrial M et al. International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. Transplantation. 2019 Jan; 103 (1): 45–56. doi: 10.1097/ TP.0000000000002433.

Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009 Apr; 9 (4): 782–793. doi: 10.1111/j.1600-6143.2009.02590.x.

Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT et al. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation. 2017 Aug; 101 (8): 1867–1874. doi: 10.1097/ TP.0000000000001709.

Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Harper AM et al. OPTN/SRTR 2016 Annual Data Report: Liver. Am J Transplant. 2018 Jan; 18 Suppl 1: 172– 253. doi: 10.1111/ajt.14559.

Van den Berg EH, Douwes RM, de Meijer VE, Schreuder TCMA, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018 Jan; 50 (1): 68–75. doi: 10.1016/j.dld.2017.08.022.

Germani G, Laryea M, Rubbia-Brandt L, Egawa H, Burra P, O Grady J, Watt KD. Management of Recurrent and de novo NAFLD/NASH After Liver Transplantation. Transplantation. 103 (1): 57–67, JAN 2019 doi: 10.1097/TP.0000000000002485.

Stine JG, Argo CK, Pelletier SJ, Maluf DG, Caldwell SH, Northup PG. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017 Jan 28; 9 (3): 139–146. doi: 10.4254/wjh.v9.i3.139.

Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141 (4): 1249–1253. doi: 10.1053/j.gastro.2011.06.061.

Merola J, Liapakis A, Mulligan DC, Yoo PS. Non-alcoholic fatty liver disease following liver transplantation: a clinical review. Clin Transplant. 2015 Sep; 29 (9): 728– 737. doi: 10.1111/ctr.12585.

Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. J Clin Gastroenterol. 2018 Apr; 52 (4): 339–346. doi: 10.1097/ MCG.0000000000000925.

Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 2012 Jan; 18 (1): 29– 37. doi: 10.1002/lt.22435.

Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015 Mar; 148 (3): 547–555. doi: 10.1053/j.gastro.2014.11.039.

Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P et al. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017 Oct; 62 (10): 2915–2922. doi: 10.1007/s10620-017-4684-x.

Thuluvath AJ, Chen PH, Thuluvath PJ, Kantsevoy S, Savva Y. Poor Survival After Retransplantation in NASH Cirrhosis. Transplantation. 2019 Jan; 103 (1): 101–108. doi: 10.1097/TP.0000000000002135.

El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant. 2012 Sep-Oct; 26 (5): E505–512. doi: 10.1111/ctr.12014.

Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 2009 Dec; 15 (12): 1814–1820. doi: 10.1002/lt.21927.

Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation. 1996 Dec 27; 62 (12): 1802–1805.

Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg. 1997 Mar; 3 (2): 177–178.

Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int. 2013 Jan; 26 (1): 67–74. doi: 10.1111/j.1432-2277.2012.01576.x.

Miyaaki H, Miuma S, Taura N, Shibata H, Sasaki R, Soyama A et al. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation. Transplantation. 103 (1): 109–112, JAN 2019. doi: 10.1097/ TP.0000000000002319.

Kardashian AA, Dodge JL, Roberts J, Brandman D. Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int. 2018 Mar; 38 (3): 553–563. doi: 10.1111/liv.13523.

Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011 Oct; 54 (4): 1208–1216. doi: 10.1002/hep.24491.

Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Mar; 12 (3): 394–402.e1. doi: 10.1016/j. cgh.2013.09.023.

The authors declare that there are no conflicts of interest present.